This month, NuVasive (NUVA) will launch the XLIF® Lordotic Expandable interbody system (XLX) for XLIF anterior column realignment (ACR), a minimally disruptive alternative to open procedures. The system received FDA 510(k) clearance in May.
The XLX ACR system addresses sagittal alignment from the anterior column while reducing blood loss and length of hospital stay. It will be offered in a range of sizes with up to 30 degrees of customizable lordosis, and will work with NUVA's Surgical Intelligence platform that will integrate neuromonitoring, surgical planning, radiation reduction, navigation/imaging, cloud integration/data connectivity and data insights/smart tools to optimize O.R. time.
XLX ACR joins NUVA's expandable interbody portfolio of TLX™ and MLX®.
Sources: NuVasive, Inc.; FDA.gov